• Net sales were TSEK 7,248 (4,941), +47%.
• The loss after tax was TSEK 12,786 (8,765).
• The loss per share was SEK 0.11 (0.13).
• The cash flow from current operations was negative in the amount of TSEK 17,827 (9,718).
• The gross margin was 68.2% (58.4%).
• Electrode sales volume increased by 60% and was 16,922 (10,592) units. Repeat sales of electrodes to existing customers increased by 66%.

• Net sales were TSEK 17,481 (12,927), +35%.
• The loss after tax was TSEK 35,044 (27,713).
• The loss per share was SEK 0.34 (0.40).
• The cash flow from current operations was negative in the amount of TSEK 34,633 (29,783).
• The gross margin was 67.5% (63.3%).
• Electrode sales volume increased by 32% and was 39,866 (30,172) units. Repeat sales of electrodes to existing customers increased by 33%.

• Overall sales increased by 47% (+33, before currency effects). Sales in Germany increased by 65% (49% in local currency).  Sales in the US skin cancer market was 31% lower than Q3 2022. Sales within the skin barrier segment increased by 42%.

• SciBase appointed Pia Renaudin as new Chief Executive Officer.

• SciBase signed new collaboration agreement with Bare Dermatology to advance skin cancer detection in Texas.

• SciBase strengthens US team with experienced Dermatology executive.

• A study was published in the journal Allergy showing that Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis. The study was performed together with the University Children's Hospital Zürich.

• The results from a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland was published in the journal Allergy. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.

• A nominating committee for the Annual General Meeting in 2024 was appointed.

Financial overview   

Oct 1,
2022 - 
July Jan 1 Sep 30, Jan 1 - Dec 31
1 - - Sep 2023
Sep 30
30
THE GROUP 2023 2022 2023 2022 Rolling 2022
-12
Net sales, SEK ths 7 248 4 941 17 12 22 444 17 890
481 927
Gross margin, % 68,2% 58,4% 67,5% 63,3% 66,1% 62,8%
Equity/Asset ratio, % 72,4% 72,5% 72,4% 72,5% 72,4% 50,6%
Net indebtness, multiple 0,38 0,38 0,38 0,38 0,38 0,98
Cash equivalents, SEK ths 52 34 52 34 52 353 18 832
353 014 353 014
Cashflow from operating -17 -9 -34 -29 -49 225 -44 466
activities, SEK ths 827 718 633 873
Earnings per share -0,11 -0,13 -0,34 -0,40 -0,53 -0,63
(before and after
dilution), SEK
Shareholder's equity per 0,50 0,57 0,58 0,57 0,52 0,37
share, SEK
Average number of shares, 119 68 104 68 95 141 68 475
000' 831 475 029 475
Number of shares at 119 68 119 68 119 831 68 475
closing of period, 000'* 831 475 831 475
Share price at end of 1,24 3,70 1,24 3,70 1,24 3,82
period, SEK
Number of sold 16 10 39 30 51 406 41 712
electrodes, pieces 922 592 866 172
Average number of 23 20 22 19 21 20
employees

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 10, 2023.

This report has been comprehensively reviewed by the Company's auditors.

Contact person:

Michael Colérus, CFO, +46 70 341 34 72

For more information, please contact:
Pia Renaudin, CEO SciBase
Tel: +46 73 206 98 02
Email: pia.renaudin@scibase.com (simon.grant@scibase.com)

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: ca@vatorsec.se

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases